Common GI side effects (affecting more than 1 in 10 people) according to the SmPC: Nausea : The most frequent side effect, reported in approximately 44% of patients in clinical trials, usually most pronounced during the first few weeks and with dose increases Diarrhoea : Affects roughly 30% of users, typically mild to moderate and transient Vomiting : Occurs in about 24% of patients, often associated with eating too quickly or consuming large portions Constipation : Reported in approximately 24% of users, which may require dietary modification or occasional laxative use Abdominal pain or discomfort : Affects around 20% of patients, usually described as cramping or bloating Dyspepsia and reflux : Indigestion and heartburn occur in approximately 9% of users Less common but significant GI effects : Delayed gastric emptying : Whilst this is the intended pharmacological effect, in some cases it can cause persistent nausea, vomiting, and inability to tolerate food Pancreatitis : Has been reported in clinical trials and post-marketing

Abnormal estrogen signaling through ER is a major driver of tumorigenesis in luminal A and luminal B breast cancers [4], as it promotes the proliferation of cancer cells by overexpressing cyclin D1 and c-Myc, both of which enable the tumors to bypass the G1/S checkpoint [5]
This distinction matters because the two causes respond to different interventions
The questionnaire is used by CareValidate Health to apply exclusionary criteria, meaning the answers determine whether the individual is screened out of eligibility before any clinician consultation occurs
Whole-Body Wellness - We go beyond the number on the scale
So we're not really comparing apples to apples